The number of persons with diabetes is projected to grow from 463 million to 700 million worldwide between 2019 and 2045, with the greatest effect occurring in low- and middle-income countries.1 Given the growing number of cases of diabetes (90% of which are type 2), an increased incidence of complications of diabetes, particularly cardiovascular disease and chronic kidney disease, is anticipated.2,3 The need is urgent to develop and deploy effective therapies for diabetes — especially those that reduce the risks of serious complications — across populations. The novel concept of combining a glucose-dependent insulinotropic polypeptide with a glucagon-like peptide-1 (GLP-1) . . .